Subject Index

Aberrant lysosomal processing, role of, in Alzheimer's disease, 145-146
Acetylcholinesterase, 170
Acid hydrolases, genetic defects in, 65
Acute phase response, 161
Aging
  cellular, lipofuscin and, 66
  protease inhibition and, 89
  protein changes in, 20
Alzheimer's disease
  familial, 139
  heterogeneous disorder of, 139
  lysosomal system and (*see also* Aberrant lysosomal processing), 66
  neurodegeneration in, by excitotoxicity, 197-200
Amino acid incorporation, 17
Amino terminus of amyloid β protein precursor fragment, 139-140
Ammonium chloride, treatment of transfected Chinese hamster ovary cells by, 108
Amyloid β protein precursor, proteolytic cleavage of, 138-139
Amyloid precursor protein
  amyloidogenic degradation of, 180
  expression of, in COS cells, 54, 131
  lysosomal system in processing of, 66
Amyloid precursor protein secretase
  cleavage of full-length amyloid precursor protein by, 118
  direct phosphorylation of, 206
  normal processing of amyloid precursor protein by, 10
  proteolytic processing occurs by, 130
Amyloidosis, Dutch form of cerebral hemorrhage with, 167
Angiotensin-converting enzyme, 83
α1-Antichymotrypsin
  Alzheimer amyloid deposits and, 161
  cleavage of peptide inhibited by, 175
Anticoagulant, protease nexin-2/β-amyloid protein precursor as, 243
Antisense-RNAs, production of, 224
Antithrombin, protease nexin-1 as, 244
Aprotinin, use of, as a protease inhibitor, 90
Astrocyte stellation, regulation of, 230-231
Astrocytes
  α1-antichymotrypsin expression and, 167
  cathepsin H and cathepsin G identified in, 69
  glia-derived nexin synthesized by, 237
  role of, in amyloidogenesis, 174
Autophagy, shifts in intralysosomal pH during, 83

Band-3, 181-183
Blood vessel walls, proteins in, 246
Body temperature, protein synthesis rates effected by change in, 22
Brain
  human, Kunitz-type serine inhibitors and, 244
  monkey
    age-related diseases and, 89
    screening of, for enzymes, 175
  rat
    age-related diseases and, 89
    clipsin-like proteases in, 162
    protein turnover rates in, 16
    tissue slices in, 19
Brefeldin A
  addition of, during labelling period, 106
  treatment of PC12 cells with, 208

C-Fos, hydrolyzation of, by calpains, 224
c-Jun, hydrolyzation of, by calpains, 224
Calcium, procalpain translocated by, 222
Calcium-activated serine protease, monkey brain containing, 175
Calcium-binding proteins, activities and structures of, 218
Calcium/calmodulin-dependent protein kinase II, 204
Calcium ionophore, activation of calpain and, 221
Calpain
  calcium ions and, 218
  cerebral levels of, in aging, 20
  first discovery of, 8
Calpain I, involvement of, in excitotoxicity, 194-197
m-Calpain, 195
μ-Calpain, 195
Calpastatin, inhibition of calpain by, 23, 224
Carboxyl terminus of amyloid β protein precursor fragment, 139
Carnitine
  calpains activated by, 23
  isovaleryl, 23
Cathepsin B
  catalyzation by, 3
  cleavage of full-length amyloid precursor protein by, 130
Cathepsin D
  immunocytochemical studies using, 67

inhibition of, by pepstatin, 2
protein changes in aging and, 20
Cathepsin E, 10
Cathepsin G
clipsin-like protease/rat mast cell protease-1 and, 164
immunocytochemical studies using, 67
serine protease and, 175
Cathepsin H
immunocytochemical studies using, 67
properties of, 3
Cathepsin L
immunocytochemical studies using, 67
properties of, 3
Cathepsin S, 3
cDNA
α1-antichymotrypsin, 164
chimeric, 55
Chinese hamster ovary cells transfected with, 105
transfected, 223
cDNA clones, cathepsin G antibodies and, 177
Cell death, lysosomal system and, 65-66
Cells
Chinese hamster ovary, 53, 105
COS, 54, 131, 223
endothelial, 246
HeLa, 223
I, 105, 108
PC12, 38-50, 120
Schwann, 237
Ceroid, 65
Chaperone, 107
Chinese hamster ovary cell
plasma membrane precursors and, 53
transfection of, 105
Chloroquine
acid-dependent proteolysis inhibited by, 208
addition of, during chase, 106
PC12 cell cultures treated with, 121
use of, as a protease inhibitor, 90
Chromatolytic changes, neurons exhibiting, 69
Chromogranin B, labeling of, by radioactive sulfate, 39
Chromosome 21, loci on, increased dosage of, 139
Chymotrypsin, 162
Clipsin, 162
Coagulation factor XIa, 246
Contrapsin, 164
Cystatin A, 3-4
Cystatin B, 3-4
Cysteine protease
cleavage of full-length amyloid precursor protein by, 176
lysosomal, inhibiting, 83
Cysteine proteinase, cytosolic, 218
Cytoskeleton, 180

Dense bodies, dystrophic neurites containing, 77
Derivatives, carboxyl-terminal amyloid β protein precursor, 142
Diacylglycerol, activity of novel protein kinase C dependent on, 223
Dolichols, increase of, in senescent brain, 91
Dutch form of cerebral hemorrhage (*see* Amyloidosis)

E64C, use of, as a protease inhibitor, 90, 106
Endocytic pathway, inhibition of proteolysis in, 208
Endocytosis, rapid, 53
Endopeptidase, multicatalytic, 8
Endopeptidases, classification of, 1
Endoplasmic reticulum
endopeptidases of posttranslational processing in, 5
newly synthesized proteins in, 208
proteins integrated into, 27
Endosomal/lysosomal pathway, derivatives generated by, 143
Endosome(s)
C-terminal fragments in, 113
early and late, 208
lysosomes and, 2
materials shuttled to lysosome by, 65
translocation of proteins within, 27
Endothelial cells, upregulation of β-amyloid protein precursor in, 246
Enteropeptidase, 9
Entorhinal cortex, 56
Enzyme
endothelin-converting, 10
interleukin-converting, 9
ubiquitin-conjugate-degrading, 8
Epidermal growth factor, receptors for, 53
Epidermal growth factor binding protein, 246
Epidermal growth factor receptor, 204
Excitotoxicity, overview of, 193-194
Exopeptidases, classification of, 1
Extracellular matrix, protease nexin-1 binds tightly to, 229

Fibrin, blood clot formation and, 246
Fibroblasts
defective I cell, 105
human, Kunitz-type serine inhibitors and, 244
Fodrin, hydrolysis of, 220

Gelsolin, 181
Glial-derived nexin, neurite outgrowth stimulated by, 229
Glucocorticoids, concentration of, 167
β-Glucuronidase, 152
Glycosaminoglycans, protease nexin-2 and, 246
Glycosylation
  detection of, in chase, 107
  N-linked, 34
Golgi
  destruction of by brefeldin A, 107
  early, 208
  endopeptidases of posttranslational processing in, 5
  PC12 cells and, 38-50
  translocation of proteins within, 27
Granule protein, platelet α, 246

Heat shock protein 70
  degradation of proteins and, 61
  uptake of proteins into lysosomes and, 152
HeLa cells, transcription of calpain gene in, 223
Hemostasis, protease nexin-2 and, 246
Hepsin, 9
Hereditary cerebral hemorrhage with amyloidosis of the Dutch-type, 212
β-Hexosaminidase A, 67
Huntington's disease, lysosomal system and, 66

I cell disease, 108
Immunoelectron microscopy, activation of calpain studies by, 222
Immunoprecipitation analysis, 105
Inflammation, proteases expected to cause, 166
Insulinase, 8
Interleukin-1, upregulation of β-amyloid protein precursor by, 246
Interleukin-2 receptor, 204
Interleukins, 157
Intracellular trafficking, phosphorylation of amyloid protein precursor and, 204-206
Ischemic insult, 238

Jun D, hydrolyzation of, by calpains, 224

Kexin, 6
Kunitz-type serine inhibitors, 243

Lesion
  glia-derived nexin and, 237-238
  hippocampal, 238
Leupeptin
  C-terminal stub and, 107
  production of nexin-2 and, 121
  use of, as a protease inhibitor, 90
Lewy body, gelsolin in, 186
Lipofuscin
  accumulation of, in the cytoplasm, 89
  lysosomal system and, 65
Lysosomal protease inhibitors, cultures treated with, 105
Lysosomal targeting, defective I cel fibroblasts and, 105
Lysosome systtem, 151
Lysosomes
  amyloid precursor protein secretase activity in, 134-135
  early and late, 208
  effect of chloroquine on, 121
  endosomes and, 2
  markers of, 67
  ribonuclease A degraded within, 59
  translocation of proteins within, 27

Macroautophagy, 58
Malnutrition, brain protein content resulting from, 16
Mannose 6-phosphate receptor, defective, 108
Membrane proteins, oxidative injury to, by free radicals, 79
Membrane-cytoskeleton complex, 180
Membranes
  activation of calpain in absence of, 222
  oxidative injury to, by free radicals, 79
Meninges, 164
Meprin A, 10
Microautophagy, 58
Microglia, 165-166
Microtuble, transport system based on, 82
Minigenes, 53
Monensin, distal Golgi function inhibited by, 208
Mucolipidosis II, 108
Multivesicular bodies, 150

Neomycin, activation of calpain and, 221
Neprilysin, 10
Nerve growth factor, 246
Nervous system, 240-241
Neurite retraction, thrombin-induced, 237
Neurofilament polypeptides, calpains degrade components of, 197
Neurofilaments, antibodies directed against, 91
Neurolysin, 9
Nexin-1
  expression of, in central nervous system, 237

location of, in brain, 244
regulation of neuronal cells by, 228-234
Nexin-2
cellular association of, 120-121
overexpressed amyloid precursor protein processed into, 134
role of, as cerebral anticoagulant, 243
Nutritional deprivation, degradation of proteins and, 61

Okadaic acid, phosphorylation of amyloid precursor protein and, 204
Oligopeptidase
prolyl, 8
thimet, 9
Oxidative injury (*see* Membranes)

Paired helical filaments, Alzheimer's disease brain and, 89
Papain family, cysteine endopeptidases of, 3
Pathway
perforant, in rat central nervous system, 56
secretory, metabolism of amyloid precursor protein through, 83
PC12 cells
leupeptin-treated, 107
phophorylation of amyloid precursor protein and, 206
Peptidase
leader, 6
mitochondrial intermediate, 6
signal peptide, 6
Peptide recognition protein 73, 61
Peripheral nervous system, rat, 55
PEST proteins, short-lived, 224
Phorbol ester
activation of protein kinase C and, 225
amyloid precursor protein processing accelerated by, 206
Phosphatidylinositol, reduction of calcium concentration by, 220
Phosphatidylinositol-4, 5-bisphosphate, 220
Phospholipase C, inhibition of, by neomycin, 221
Phospholipids, interaction with, 219
Phosphorylation, 188
Plasma, heparinized, 246
Plasma membrane, β-amyloid precursor protein cleavage on, 53
Plasminogen activators
effects of, on neuron, 234
urokinase and tissue, 10
Platelets, human, Kunitz-type serine inhibitors and, 244
Polyamines, cerebral calpain activity increased by, 23
Prion encephalopathies, lysosomes and, 152
Proenzyme, inactive, 223
Protease, mast cell, 162
Proteasome, 8
Protein(s), 8
docking, 29-30
guanine nucleotide exchange (release), 32
heat shock 70, 61, 152
membrane, classification of, 27
peptide recognition 73, 61
secretory, 49
Protein C, anticoagulant effect of, 248
Protein insertion, 30
Protein integration, 30-31
Protein kinase C
interaction of calpain with, 222-224
phosphorylation of amyloid precursor protein by, 204
Protein kinase inhibitors, 240
Protein kinases, purified, 204
Protein phosphatases, inhibition of, by okadaic acid, 206
Protein phosphorylation, aberrant, 204
Protein sorting, signal recognition particle and, 29
Protein synthesis, effect of nutrition on, 16
Protein targeting, 29-30
Protein turnover rates, 16
Proteoglycans, PC12 cells and, 38-50
Proteolysis
limited, 225
lysosomal, 121

Ribophorin, 30

Scrapie, 149
Secretion, constitutive, efficiency of, 41
Secretogranin II, labeling of, by radioactive sulfate, 39
Secretory cleavage pathway, targeting of amyloid precursor protein molecules and, 208
Secretory granules, chromogranin B in, 43
Secretory vesicles
endopeptidases of posttranslational processing in, 5
PC12 cells and, 38-50
Serine protease inhibitor, 237
Signal peptidase, eukaryotic, 34
Signal recognition particle, 29
Signal sequences, protein sorting reaction and, 28-29
Spectrin
abnormal proteolysis of, 180-181
calpains degrade components of, 197
Spermine, cerebral calpain activity increased by, 23

Staurosporine, 240
Stefin A, 3-4
Stefin B, 3-4

Targeting signal, putative endocytic, 53
Tau, antibodies to, 93
Thrombin
  activation of calpain and, 221
  anion-binding exocite, 239
  blood coagulation initiated by, 246
  membrane-bound tubulin attacked by, 20
  regulation of neuronal cells by, 228-234
  role of, in the nervous system, 238-239
Thrombin receptor, 239
Thrombomodulin, anticoagulant function of, 247-248
Transcription factors, effect of calpain on, 224
Transfected cells, amyloid precursor protein, 106
Transgenic mice, pathologic potential of amyloid precursor proteins *in vivo* in, 177
Translocon, 35
Transport, axonal, in rat peripheral nervous system, 55
Tubulin, degradation of, by cathepsin D, 20

Ubiquitin
  lysosomal system and, 151
  monoclonal antibodies to, 93-94
Urokinase plasminogen activator, 234

Vitamin E, deficiency of, 83

Index of Contributors

Abraham, C. R., 174-179

Banay-Schwartz, M., 16-26
Barrett, A. J., 1-15
Baum, L., 180-192
Bell, L., 103-117
Buxbaum, J. D., 203-217

Caporaso, G. L., 203-217
Cataldo, A. M., 65-88
Cole, G. M., 103-117
Cunningham, D. D., 228-236
Czernik, A. J., 203-217

Das, S., 161-173
Dice, J. F., 58-64
Dressler, D., 161-173
Dunlop, D., 16-26

Estus, S., 138-148

Flanagan, L., 180-192

Gandy, S. E., 203-217
Gilmore, R., 27-37
Golde, T. E., 138-148
Greengard, P., 203-217
Grimes, M., 38-52

Hamilton, D. J., 65-88
Hirai, S., 218-227
Hope, J., 149-160

Ishiura, S., 129-137
Iverfeldt, K., 203-217
Ivy, G. O., 89-102

Kanaley-Andrews, L., 65-88
Kanemaru, K., 174-179
Kay, M. M. B., 180-192
Kayyali, U. S., 161-173
Kellaris, K. V., 27-37
Kelly, R. B., 38-52

Lajtha, A., 16-26
Landon, M., 149-160
Laszlo, L., 149-160
Lowe, J., 149-160

Maruyama, K., 129-137
Masliah, E., 180-192
Mayer, R. J., 149-160
Meckelein, B., 174-179
Monard, D., 237-242
Mucke, L., 174-179

Nairn, A. C., 203-217
Nelson, R. B., 161-173
Nitsch, C. 237-242
Nixon, R. A., 65-88
Nordstedt, C., 203-217

Papastoitsis, G., 174-179
Pappolla, M. A., 118-128
Paskevich, P. A., 65-88
Picard, E., 174-179
Potter, H., 161-173

Ramabhadran, T. V., 203-217
Razzaboni, B. L., 174-179
Refolo, L. M., 118-128
Robakis, N. K., 118-128

Saido, T. C., 218-227
Saitoh, T., 103-117, 180-192
Sambamurti, K., 118-128
Schmaier, A. H., 243-252
Shioi, J., 118-128
Siman, R., 161-173, 193-202
Sisodia, S. S., 53-57
Suidan, H. S., 237-242
Sundsmo, M., 180-192
Suzuki, K., 218-227
Suzuki, T., 203-217

Tagawa, K., 129-137
Truong, Q. B., 103-117

Van Nostrand, W. E., 243-252
Vikramkumar, R., 180-192

Wagner, S. L., 243-252
Wheelock, T. R., 65-88

Younkin, S. G., 138-148